Clinical Commander

Back to dossier
cardio.cardiorenal.chronic.v1PRODUCTION
cardio.cardiorenal.chronic.v1

Chronic cardiorenal syndrome (CRS type 2/4, cross-system)

cardiologychronicadult
Hard-required inputs
0 / 7
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Classify CRS type (2 vs 4) + HF phenotype + CKD stage; identify lead problem

Inputs
2
Actions
0
Advance rule
Set
Advance when

CRS type + phenotype framed

Patient inputs (11)

Geriatric-frailty overlap; advanced-therapy candidacy

HFrEF vs HFpEF/HFmrEF determines GDMT (SGLT2i universal; finerenone ≥40; ARNi/BB by EF)

Type 2 (HF→CKD) vs type 4 (CKD→cardiac) shapes the lead problem

Congestion vs euvolemia drives diuretic strategy + distinguishes pseudo-WRF

eGFR gates SGLT2i (≥20), finerenone (≥25), RASi titration; trajectory

Permissive worsening renal function (≤~30% rise) is acceptable on GDMT

Hyperkalemia is the dominant barrier to RASi/MRA — enable, do not abandon

DM cardiorenal — SGLT2i + finerenone + GLP-1 synergy

RAS/SGLT2i/finerenone contraindicated in pregnancy

Albuminuria — finerenone benefit + CKD risk + cardiorenal prognosis

Iron deficiency common in cardiorenal — IV iron

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (9)

9 need judgement
  • informationallife_threateningadvanced_cardiorenal_branch
    End-stage cardiorenal (eGFR severely reduced + refractory HF) — combined heart-kidney transplant / LVAD / palliative pathway — 2022 ACC/AHA HF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverehyperkalemia_enablement_branch
    K 5.1–6.0 limiting RASi/MRA — add patiromer/SZC + dietary K + review K-sparing co-meds to KEEP GDMT (severe/ECG hyperK → emergency pathway) — 2022 ACC/AHA HF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverediuretic_resistance_branch
    Diuretic-resistant congestion — sequential nephron blockade (loop + metolazone ± acetazolamide/SGLT2i), then ultrafiltration if refractory — 2022 ACC/AHA HF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepregnancy_special_pop
    Pregnancy with cardiorenal disease — STOP RAS/SGLT2i/finerenone/spironolactone; BB ± hydralazine + careful volume; cardio-obstetric + nephrology — ESC 2018 Pregnancy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereckd_progression_branch
    Accelerated eGFR decline / rising UACR — KDIGO risk-based intensification + nephrology co-management — KDIGO 2024
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepermissive_wrf_do_not_abandon_gdmt
    Creatinine rise ≤~30% (or eGFR drop) after RASi/SGLT2i/MRA initiation without hypovolemia/AKI features — permissive; CONTINUE GDMT (do not reflexively stop) — 2022 ACC/AHA HF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatedm_cardiorenal_branch
    DM + CKD + HF triad — SGLT2i + finerenone + GLP-1 RA synergy; intensify cardiorenal-metabolic therapy — ADA 2026; FIDELIO/FIGARO
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepseudo_wrf_branch
    Rising creatinine during effective decongestion with improving congestion/hemoconcentration — pseudo-worsening renal function; continue decongestion (do not stop diuretics) — 2022 ACC/AHA HF
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateanemia_iron_branch
    Iron deficiency / anemia in cardiorenal — IV iron (ferric carboxymaltose); ESA per nephrology if CKD anemia — AFFIRM-AHF; KDIGO 2024
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Cardiorenal — shared SGLT2i/finerenone pillar + RASi-enablement + decongestion (2022 AHA/ACC/HFSA HF; KDIGO 2024)
axis: cardiorenal_shared_pillar_and_hyperK_enablementstep 1 - Step 1 — SGLT2i: the shared HF + CKD (+ DM) pillar
Selected step "Step 1 — SGLT2i: the shared HF + CKD (+ DM) pillar" — Cardiorenal syndrome, eGFR ≥20, no active DKA, not pregnant
  • dapagliflozin
    first line
    SGLT2i
    10 mg • PO • once daily
    triggers: cardiorenal_eGFR>=20
    DAPA-HF/DELIVER (HF) + DAPA-CKD (CKD) — single agent benefits both organs; 2022 ACC/AHA HF + KDIGO 2024 Class I
    rxcui 1488564
  • empagliflozin
    first line
    SGLT2i
    10 mg • PO • once daily
    triggers: cardiorenal_eGFR>=20
    EMPEROR-Reduced/Preserved + EMPA-KIDNEY — cardiorenal benefit across spectrum (2022 ACC/AHA HF; KDIGO 2024)
    rxcui 1545653

outpatient playbook — drug actions (4)

  1. 1. SGLT2i (shared pillar)
    dapagliflozin/empagliflozin 10 mg • PO • daily
    trigger: eGFR ≥20 (KDIGO 2024)
    Single agent benefits HF + CKD
  2. 2. finerenone/MRA + RASi (permissive WRF)
    finerenone 10–20 mg; ARNi titrated • PO • daily/BID
    trigger: eGFR ≥25, K ≤5.0 (FIDELIO/FINEARTS-HF)
    Cardiorenal event reduction; tolerate ≤30% creatinine rise
  3. 3. K-binder to enable RASi/MRA
    patiromer 8.4 g / SZC 5–10 g daily • PO • daily
    trigger: K 5.1–6.0 limiting RASi (2022 ACC/AHA HF)
    Enable, not abandon, GDMT
  4. 4. diuretic strategy + IV iron
    loop ± metolazone; ferric carboxymaltose • PO/IV • per protocol
    trigger: Congestion / diuretic resistance / iron deficiency
    Sequential nephron blockade; IV iron reduces HF hosp

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Worsening renal function during HF GDMT titration; HF + CKD (bidirectional cardiorenal); Hyperkalemia limiting RASi/MRA up-titration.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Chronic cardiorenal syndrome (CRS type 2/4, cross-system)** (cardio.cardiorenal.chronic.v1).
Phenotype framing: CRS type 2 vs 4 vs prerenal vs intrinsic; true vs pseudo-worsening renal function (hemoconcentration with decongestion)
Scope: Classify CRS type (2 vs 4) + HF phenotype + CKD stage; identify lead problem

No severity triggers fired against current inputs.

Plan

Regimen axis: **Cardiorenal — shared SGLT2i/finerenone pillar + RASi-enablement + decongestion (2022 AHA/ACC/HFSA HF; KDIGO 2024)** — step "Step 1 — SGLT2i: the shared HF + CKD (+ DM) pillar".
1. dapagliflozin 10 mg PO once daily (SGLT2i, first line) — DAPA-HF/DELIVER (HF) + DAPA-CKD (CKD) — single agent benefits both organs; 2022 ACC/AHA HF + KDIGO 2024 Class I
2. empagliflozin 10 mg PO once daily (SGLT2i, first line) — EMPEROR-Reduced/Preserved + EMPA-KIDNEY — cardiorenal benefit across spectrum (2022 ACC/AHA HF; KDIGO 2024)

Setting playbook (outpatient) — Maximise shared SGLT2i/finerenone pillar, keep RASi/MRA on board via hyperK enablement + permissive WRF, decongest, IV iron, timely advanced therapy (2022 AHA/ACC/HFSA HF; KDIGO 2024)
3. SGLT2i (shared pillar) dapagliflozin/empagliflozin 10 mg PO daily — eGFR ≥20 (KDIGO 2024) (Single agent benefits HF + CKD)
4. finerenone/MRA + RASi (permissive WRF) finerenone 10–20 mg; ARNi titrated PO daily/BID — eGFR ≥25, K ≤5.0 (FIDELIO/FINEARTS-HF) (Cardiorenal event reduction; tolerate ≤30% creatinine rise)
5. K-binder to enable RASi/MRA patiromer 8.4 g / SZC 5–10 g daily PO daily — K 5.1–6.0 limiting RASi (2022 ACC/AHA HF) (Enable, not abandon, GDMT)
6. diuretic strategy + IV iron loop ± metolazone; ferric carboxymaltose PO/IV per protocol — Congestion / diuretic resistance / iron deficiency (Sequential nephron blockade; IV iron reduces HF hosp)

Non-pharmacologic actions:
- Cardio-renal joint clinic co-management — KDIGO 2024
- Nephrotoxin/contrast avoidance + medication reconciliation — KDIGO 2024
- Advanced HF / combined heart-kidney transplant evaluation when end-stage — 2022 ACC/AHA HF

AVOID / contraindication checks:
- Do not abandon RASi for permissive creatinine rise up to ~30pct — 2022 ACC/AHA HF
- Treat hyperkalemia with binders to enable RASi MRA not withdraw — 2022 ACC/AHA HF
- SGLT2i is the shared HF CKD pillar continue to eGFR 20 — KDIGO 2024
- Finerenone block if K gt 5.0 or eGFR lt 25 — FIDELIO/FINEARTS HF
- RAS SGLT2i finerenone contraindicated in pregnancy — switch to BB ± hydralazine
- Distinguish pseudo WRF hemoconcentration from true AKI before stopping decongestion — 2022 ACC/AHA HF

Monitoring

Regimen monitoring:
- BMP eGFR K 1-2wk after RASi MRA SGLT2i change then periodic — 2022 ACC/AHA HF; KDIGO 2024
- K after finerenone start and each titration — FIDELIO
- UACR and eGFR slope for CKD progression — KDIGO 2024
- weight and congestion for diuretic titration — 2022 ACC/AHA HF
- iron studies q6m until repleted — AFFIRM-AHF

Setting (outpatient) monitoring:
- eGFR/K cadence after every RASi/MRA/SGLT2i change — 2022 ACC/AHA HF
- UACR + eGFR slope; congestion/weight — KDIGO 2024

Follow-up plan: Lifelong cardiorenal co-management; advanced-therapy timing; re-phenotype
- Close-out criterion: lifelong cardiorenal plan documented

Monitoring phase: eGFR/K cadence after RASi/MRA/SGLT2i changes; congestion + weight; iron repletion

Disposition

Current setting: outpatient — Maximise shared SGLT2i/finerenone pillar, keep RASi/MRA on board via hyperK enablement + permissive WRF, decongest, IV iron, timely advanced therapy (2022 AHA/ACC/HFSA HF; KDIGO 2024)

Disposition criteria:
- Stable cardiorenal on shared pillars → joint-clinic surveillance
- HyperK-limited → binder + continued GDMT
- End-stage → advanced-therapy/transplant pathway

Escalation triggers (move to higher acuity):
- Severe hyperK / refractory congestion / uremia → acute cardiorenal pathway — 2022 ACC/AHA HF
- eGFR <20 + persistent volume issues → SGLT2i reassessment + nephrology — KDIGO 2024
- End-stage cardiorenal → ultrafiltration / heart-kidney transplant — 2022 ACC/AHA HF

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] End-stage cardiorenal (eGFR severely reduced + refractory HF) — combined heart-kidney transplant / LVAD / palliative pathway — 2022 ACC/AHA HF
- [SEVERE] K 5.1–6.0 limiting RASi/MRA — add patiromer/SZC + dietary K + review K-sparing co-meds to KEEP GDMT (severe/ECG hyperK → emergency pathway) — 2022 ACC/AHA HF
- [SEVERE] Diuretic-resistant congestion — sequential nephron blockade (loop + metolazone ± acetazolamide/SGLT2i), then ultrafiltration if refractory — 2022 ACC/AHA HF

Citations

- 2022 AHA/ACC/HFSA HF Guideline + KDIGO 2024 CKD Guideline; DAPA-HF/DELIVER/DAPA-CKD/EMPA-KIDNEY; FIDELIO/FIGARO/FINEARTS-HF [PMID:35379504](https://pubmed.ncbi.nlm.nih.gov/35379504/)
- Cited evidence (PMID 37622666) [PMID:37622666](https://pubmed.ncbi.nlm.nih.gov/37622666/)
- Cited evidence (PMID 31535829) [PMID:31535829](https://pubmed.ncbi.nlm.nih.gov/31535829/)
- Cited evidence (PMID 32865377) [PMID:32865377](https://pubmed.ncbi.nlm.nih.gov/32865377/)
- Cited evidence (PMID 36027570) [PMID:36027570](https://pubmed.ncbi.nlm.nih.gov/36027570/)

Last reconciled with current guidelines: 2026-05-16.
References
  • 2022 AHA/ACC/HFSA HF Guideline + KDIGO 2024 CKD Guideline; DAPA-HF/DELIVER/DAPA-CKD/EMPA-KIDNEY; FIDELIO/FIGARO/FINEARTS-HF — PMID:35379504
  • Cited evidence (PMID 37622666) — PMID:37622666
  • Cited evidence (PMID 31535829) — PMID:31535829
  • Cited evidence (PMID 32865377) — PMID:32865377
  • Cited evidence (PMID 36027570) — PMID:36027570